Screener
Ligand Pharmaceuticals LGND Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $78.75M-31.8% | $63.69M+33.7% | $51.72M+14.1% | $59.67M+39.4% | $115.46M+123% | ||
| $2.77M-86.8% | $14.67M+123% | $2.15M-95.7% | $3.51M-20.7% | $21.02M+270% | ||
| $72.62M+155% | $29.12M+44.4% | $20.84M+10.8% | $25.03M-2.3% | $28.45M+16.2% | ||
| $94.5M+56.1% | $55.1M+40.6% | $34.35M-57.9% | $45.82M-12.6% | $60.53M+24.4% | ||
| -$15.76M-129% | $8.59M+1.7% | $17.37M+148% | $13.84M+244% | $54.93M+1,648% | ||
| -20%-67.6pp | 13.5%-4.2pp | 33.6%+113pp | 23.2%+45.7pp | 47.6%+41.5pp | ||
| $2.9M+218% | $1.75M+51.6% | $1.75M+101% | $1.79M+102% | $910K+22.8% | ||
| -$28.34M-133% | $55.71M+1,905% | -$41.63M-198% | $42.94M— | $86.21M+1,009% | ||
| -$44.09M-131% | $64.3M+473% | -$24.26M+51.7% | $56.78M— | $141.14M+2,326% | ||
| -$15.61M-165% | $15.8M+148% | -$10.91M-41.2% | $12M— | $23.86M+2,765% | ||
| -$28.49M-124% | $48.51M+901% | -$13.35M+68.6% | $44.78M+244% | $117.27M+1,735% | ||
| -36.2%-138pp | 76.2%+66.0pp | -25.8%+67.8pp | 75.1%+148pp | 101.6%+115pp | ||
| -$1.43-125% | $2.22+825% | -$0.67+69.7% | $2.18+230% | $5.68+1,556% | ||
| -$5.44M-109% | $16.81M-0.9% | $25.58M+193% | $22.06M+2,284% | $63.2M+421% | ||
| -6.9%-61.6pp | 26.4%-9.2pp | 49.5%+110pp | 37%+39.3pp | 54.7%+31.3pp | ||
| -$15.76M-129% | $8.59M+1.7% | $17.37M+148% | $13.84M+244% | $54.93M+1,648% |
FAQ
- What is Ligand Pharmaceuticals's revenue?
- Ligand Pharmaceuticals (LGND) generated $253.8M in revenue over the trailing twelve months, up 1.0% year over year.
- Is Ligand Pharmaceuticals profitable?
- Ligand Pharmaceuticals reported $51.5M in net income over the trailing twelve months, a 20.3% net margin.
- What are Ligand Pharmaceuticals's profit margins?
- Gross margin is 91.9% and operating margin is 9.5%, with a 20.3% net margin.
- What is Ligand Pharmaceuticals's earnings per share?
- Ligand Pharmaceuticals's diluted EPS over the trailing twelve months is $2.30.
- Where does Ligand Pharmaceuticals's income statement data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
